Feb 25 (Reuters) - Fresenius Se CEO Ulf Schneider
* Says to focus on small and medium sized takeovers, not thetime for large takeovers
* Says well prepared to compete with a combinedPfizer-Hospira
* Says has no plans to enter biosimilars market at themoment
* Says Kabi unit expects about 10 new drug launches in U.S.this year, maybe more
* Says Kabi unit expects U.S. organic sales growth of -3percent to +3 percent this year, time of huge growth due tosupply shortage at rivals is overFurther company coverage:
* Says to focus on small and medium sized takeovers, not thetime for large takeovers
* Says well prepared to compete with a combinedPfizer-Hospira
* Says has no plans to enter biosimilars market at themoment
* Says Kabi unit expects about 10 new drug launches in U.S.this year, maybe more
* Says Kabi unit expects U.S. organic sales growth of -3percent to +3 percent this year, time of huge growth due tosupply shortage at rivals is overFurther company coverage:
via Smart Health Shop Forum http://ift.tt/18kDhYm
No comments:
Post a Comment